TY - JOUR T1 - Chronic cough in cystic fibrosis - the effect of modulator therapy on objective 24-hour cough monitoring JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00031-2022 SP - 00031-2022 AU - Mengru Zhang AU - Kayleigh Brindle AU - Melanie Robinson AU - Debbie Ingram AU - Tanya Cavany AU - Alyn Morice Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/02/11/23120541.00031-2022.abstract N2 - Cystic fibrosis (CF) is an autosomal recessive condition, deletion of phenylalanine at position 508 (F508del) being the most frequent mutation in CF patients. Kaftrio® (also called Trikafta® in US) is a licensed modulator therapy for CF patients with at least one F508del mutation [1]. Several clinical trials have demonstrated its efficacy [2]. However, the primary outcome measured in these studies was the change in percent predicted of forced expiratory volume in one second (ppFEV1), which was in the order of 10% and thus may have a relatively low sensitivity in predicting efficacy, particularly in more severe affected patients [3].FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. ER -